Usui Takebumi, Shiozawa Shunichi, Kim Dal Ho, Tsuchiya Akira, Masuda Toshio, Inose Satoshi, Aizawa Masaki, Yoshimatsu Kazuhiko, Katsube Takao, Naritaka Yoshihiko, Ogawa Kenji
Department of Surgery, Tokyo Women's Medical University, Medical Center East.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2359-61.
We report two cases of advanced hepatocellular carcinoma( HCC) with a portal vein tumor thrombus (PVTT) responding to transcatheter arterial infusion chemotherapy (TAI) using cisplatin (CDDP). Case 1: A 65-year-old male patient was diagnosed with unresectable multiple HCCs. After 5 courses of transcatheter arterial chemoembolization (TACE), the tumor became markedly enlarged, and a PVTT (Vp2) and lymph node metastasis were noted. TAI was conducted as the second- line chemotherapy, and the liver tumor, PVTT, and lymph node metastasis shrank. The clinical response was rated as a partial response (PR). Case 2: A 72-year-old female patient was diagnosed with single HCC. After a course of TACE, the tumor became markedly enlarged and was accompanied by a PVTT (Vp4). TAI was performed as the second-line chemotherapy, and the liver tumor and PVTT significantly shrank. The clinical response was also rated as a PR. TAI using CDDP as the second-line chemotherapy for advanced HCC is a promising treatment likely to contribute to the improvement of the patient's prognosis.
我们报告了两例晚期肝细胞癌(HCC)伴门静脉癌栓(PVTT)患者,经使用顺铂(CDDP)的经动脉化疗栓塞术(TAI)治疗后有反应。病例1:一名65岁男性患者被诊断为不可切除的多发性HCC。经过5个疗程的经动脉化疗栓塞术(TACE)后,肿瘤明显增大,并发现有PVTT(Vp2)和淋巴结转移。TAI作为二线化疗进行,肝脏肿瘤、PVTT和淋巴结转移均缩小。临床反应被评为部分缓解(PR)。病例2:一名72岁女性患者被诊断为单发HCC。经过一个疗程的TACE后,肿瘤明显增大并伴有PVTT(Vp4)。TAI作为二线化疗进行,肝脏肿瘤和PVTT显著缩小。临床反应也被评为PR。使用CDDP的TAI作为晚期HCC的二线化疗是一种有前景的治疗方法,可能有助于改善患者的预后。